| answer text |
<p>The Government is assessing our existing vaccine portfolio against current variants,
working closely with vaccine manufacturers and Public Health England to understand
the efficacy of our current vaccine portfolio against new variants. <br></p><p>The
Government has also established a new partnership with the vaccine manufacturer, CureVac,
to rapidly develop new vaccines in response to new Covid-19 variants should this be
needed. The new agreement will utilise UK expertise on genomics and virus sequencing
to allow new varieties of vaccines based on messenger RNA technology to be developed
quickly against new strains of Covid-19. An initial order has been made for 50 million
doses.</p>
|
 |
